ClinicalTrials.gg
WithdrawnNCT07035119Updated Oct 6, 2026

Transcranial Magnetic Stimulation for Chronic Scrotal Content Pain

A Phase 1/2 interventional study of Transcranial magnetic stimulation in Scrotal Pain, sponsored by Medical University of South Carolina. Withdrawn at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Medical University of South Carolina · Phase 1/2, Interventional, and Treatment

How we know

Why this study was withdrawn
Study discontinued before starting
Updated Oct 6, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Pain by Medical University of South Carolina — 3 open to participants now, 3 under way, none of them phase 3. Pain · Medical University of South Carolina.

Enrollment
13th of 15
0 · median 15
Started
2026
with 2 others
Phase 1/2
Only one
of the 15
Registered
13th of 15
by date

Among the 15 studies in Pain by Medical University of South Carolina, this one is the 13th largest by enrollment, is one of 3 that started in 2026, is the only one in phase 1/2, and was the 13th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

3 of the 15 studies in Pain by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pain by Medical University of South Carolina, or all of them as a file.
02

Study summary

The purpose of this study is to perform an open label feasibility trial of TMS for the treatment of chronic scrotal content pain.

Read the detailed description

The purpose of this study is to perform an open label feasibility trial of TMS for the treatment of chronic scrotal content pain. Participants will be screened by study staff for contraindications to TMS treatment. TMS will be delivered use the MagVenture TMS machine. TMS will be delivered during 15 minutes per session, 3 sessions each day, for 3 days. A custom developed SMS text EMA system will be used to gather daily data on pain and functioning in study participants.

03

Conditions studied

  • Scrotal Pain

Browse trials for

Keywords

  • Scrotal pain
  • testicular pain
  • Transcranial magnetic stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients with chronic scrotal pain lasting for 6 or more months.
  • Pain must be present 3 or more days of the week.

Exclusion criteria

Exclusion Criteria:

  • No new pain medications within the last 30 days.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Open label

    Open label study. Participants will be screened by study staff for contraindications to TMS treatment. TMS will be delivered use the MagVenture TMS machine.

    Other: Transcranial magnetic stimulation

Interventions

  • OtherTranscranial magnetic stimulation

    Resting motor threshold will be established by first finding the area of the motor cortex associated with visible twitch of the right abductor pollicis brevis (APB). Parameter Estimation by Sequential Testing (PEST) will be conducted to quantify resting motor threshold using visible APB twitch. The left dorsolateral prefrontal cortex (DLPFC) will be located using the Beam F3 method and marked with a felt-tipped marker on the scalp. TMS will be delivered over left DLPFC at 110% of resting motor threshold at 10Hz (5-seconds-on; 10-seconds-off) for 15 minutes per session (3000 pulses), 3 sessions each day (30-minute rest in-between sessions), for 3 days (within 5 consecutive days; a total of 27,000 pulses).

06

What researchers measure

Primary outcomes

  1. Patient reported pain score on SMS text EMA system

    A custom developed SMS text EMA system will be used to gather daily data on pain

    Time frame: baseline, and post intervention (0 days, 1 week, 2 weeks, 1 month, 3 months, 6 months)

Secondary outcomes

  1. Patient reported post procedure quality of life as measured on an SMS text EMA system

    A custom developed SMS text EMA system will be used to gather daily data on pain

    Time frame: baseline, and post intervention (0 days, 1 week, 2 weeks, 1 month, 3 months, 6 months)

  2. Progression to other treatments

    Progression to other medical or surgical treatments

    Time frame: Within 6 months after completion

07

Study locations

1 site
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
08

References and documents

Publications

  • O'Connell NE, Wand BM, Marston L, Spencer S, Desouza LH. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev. 2014 Apr 11;(4):CD008208. doi: 10.1002/14651858.CD008208.pub3. PubMed 24729198 ↗
  • Hamid P, Malik BH, Hussain ML. Noninvasive Transcranial Magnetic Stimulation (TMS) in Chronic Refractory Pain: A Systematic Review. Cureus. 2019 Oct 29;11(10):e6019. doi: 10.7759/cureus.6019. PubMed 31824787 ↗
  • Parekattil SJ, Ergun O, Gudeloglu A. Management of Chronic Orchialgia: Challenges and Solutions - The Current Standard of Care. Res Rep Urol. 2020 Jul 2;12:199-210. doi: 10.2147/RRU.S198785. eCollection 2020. PubMed 32754451 ↗
  • Young NA, Sharma M, Deogaonkar M. Transcranial magnetic stimulation for chronic pain. Neurosurg Clin N Am. 2014 Oct;25(4):819-32. doi: 10.1016/j.nec.2014.07.007. Epub 2014 Aug 12. PubMed 25240669 ↗
  • Ziegelmann MJ, Farrell MR, Levine LA. Evaluation and Management of Chronic Scrotal Content Pain-A Common Yet Poorly Understood Condition. Rev Urol. 2019;21(2-3):74-84. PubMed 31768134 ↗

Individual participant data

Plan to share: No — Based on internal IRB submission, IPD will not be shared

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Apr 2030 → Sep 2026 and completion Apr 2030 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Jun 24, 2025
StartActual
Sep 23, 2026
Primary completionActual
Sep 23, 2026was Apr 2030
CompletionActual
Sep 23, 2026was Apr 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Study discontinued before starting
changed Oct 6, 2026
Start date
Sep 30, 2026→Sep 23, 2026 (actual)
Oct 6, 2026
Primary completion
Apr 1, 2030→Sep 23, 2026 (actual)
Oct 6, 2026
Study completion
Apr 1, 2030→Sep 23, 2026 (actual)
Oct 6, 2026
Enrollment
50 (estimated)→0 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Withdrawn
    Why stopped Study discontinued before starting
    Start date Sep 30, 2026→Sep 23, 2026 (now actual)
    Primary completion Apr 1, 2030→Sep 23, 2026 (now actual)
    Study completion Apr 1, 2030→Sep 23, 2026 (now actual)
    Enrollment 50 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07035119
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Sep 23, 2026
Primary completion
Sep 23, 2026
Completion
Sep 23, 2026
Last update
Oct 6, 2026

Study contacts

Jeffery Brockardt, Ph.D.
study director · Medical University of South Carolina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion